These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32160736)

  • 21. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
    Valentino JD; Li J; Zaytseva YY; Mustain WC; Elliott VA; Kim JT; Harris JW; Campbell K; Weiss H; Wang C; Song J; Anthony L; Townsend CM; Evers BM
    Clin Cancer Res; 2014 Mar; 20(5):1212-22. PubMed ID: 24443523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells.
    Pan ST; Qin Y; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1601-26. PubMed ID: 25834400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
    Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma.
    Zhao P; Hall J; Durston M; Voydanoff A; VanSickle E; Kelly S; Nagulapally AB; Bond J; Saulnier Sholler G
    PLoS One; 2017; 12(6):e0179948. PubMed ID: 28662162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
    Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
    Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.
    Amrein L; Shawi M; Grenier J; Aloyz R; Panasci L
    Int J Cancer; 2013 Jul; 133(1):247-52. PubMed ID: 23238639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
    Mehrpouri M; Momeny M; Bashash D
    J Recept Signal Transduct Res; 2022 Feb; 42(1):100-108. PubMed ID: 33969806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
    Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
    Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses proliferation and promotes apoptosis of U251 glioblastoma cells].
    Qiu Z; Yue S; Chang J; Wang G
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):936-9. PubMed ID: 27363276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
    Park E; Park J; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Int J Oncol; 2012 Apr; 40(4):1259-66. PubMed ID: 22159814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
    Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
    Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Superior Cytotoxicity of Dual Targeting of BCR/ABL and PI3K in K562 Cells: Proposing a Novel Therapeutic Potential for the Treatment of CML.
    Shiri Heris R; Pourbagheri-Sigaroodi A; Yousefi AM; Bashash D
    Indian J Hematol Blood Transfus; 2022 Jan; 38(1):51-60. PubMed ID: 35125711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
    Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
    Chuang FC; Wang CC; Chen JH; Hwang TZ; Yeh SA; Su YC
    PLoS One; 2021; 16(1):e0245715. PubMed ID: 33471836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
    Rosich L; Saborit-Villarroya I; López-Guerra M; Xargay-Torrent S; Montraveta A; Aymerich M; Villamor N; Campo E; Pérez-Galán P; Roué G; Colomer D
    Haematologica; 2013 Nov; 98(11):1739-47. PubMed ID: 23850807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A
    Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
    Bohnacker T; Prota AE; Beaufils F; Burke JE; Melone A; Inglis AJ; Rageot D; Sele AM; Cmiljanovic V; Cmiljanovic N; Bargsten K; Aher A; Akhmanova A; Díaz JF; Fabbro D; Zvelebil M; Williams RL; Steinmetz MO; Wymann MP
    Nat Commun; 2017 Mar; 8():14683. PubMed ID: 28276440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.